Search for the glycated hemoglobin target minimizing mortality among people with type 2 diabetes with rare incidence of treatment-related severe hypoglycemia - Epidemiologic analysis of J-DOIT3 randomized controlled trial.

```mdx

title: "Search for the HbA1c Target Minimizing Mortality in Type 2 Diabetes: A J-DOIT3 Landmark Analysis"

date: "2025"

category: "Research Update"

tags: ["type 2 diabetes", "HbA1c", "glycemic control", "hypoglycemia", "cardiovascular risk", "mortality", "RCT secondary analysis"]

studyType: "Randomized controlled trial (secondary epidemiologic analysis)"

sampleSize: 2542

pubmedId: "42912779"

TL;DR

In a landmark analysis of the J-DOIT3 randomized trial, participants with type 2 diabetes and rarely occurring severe hypoglycemia showed no clear lower HbA1c threshold for minimizing myocardial infarction or all-cause mortality, with an exploratory suggestion that HbA1c below 6.5% may minimize all-cause mortality.

What the study found

Type 2 diabetes management has changed considerably over the past two decades. Newer glucose-lowering drugs, along with better monitoring tools, have sharply reduced the rate of severe hypoglycemia, meaning episodes that require third-party assistance or cause serious harm. This shift raises a practical question: if the risk of low blood sugar from treatment is now small, what glycemic target minimizes the risk of the complications that matter most, namely cardiovascular events and death?

To address this, researchers used data from the Japan Diabetes Optimal Integrated Treatment study for three major cardiovascular risk factors (J-DOIT3). The trial originally enrolled 2,542 adults with type 2 diabetes and randomized them to either a conventional therapy group (n = 1,271) or an intensive therapy group (n = 1,271). Two ineligible participants were removed from all analyses afterward. Severe hypoglycemia was rare in both arms over a median follow-up of 8.5 years: 7 events in the intensive group and 4 in the conventional group.

The investigators performed a landmark analysis, starting outcome tracking at one year after baseline. At that point they used updated average values of HbA1c, systolic blood pressure, LDL cholesterol, and HDL cholesterol, and then estimated which level of each variable was associated with the lowest hazard ratios for primary and cardiovascular outcomes. Landmark analyses are a common way to reduce bias from early treatment changes, but they remain observational in nature within a trial dataset, and the results should be read as hypothesis-generating.

For glycemic control specifically, the analysis found no clear lower threshold of HbA1c associated with the lowest risk of myocardial infarction or all-cause mortality. In other words, the relationship did not show a obvious point beyond which further lowering stopped helping or began to harm. The authors did report that an HbA1c target below 6.5% could be a reasonable threshold for minimizing all-cause mortality in this population with rare severe hypoglycemia. This is the key figure in the abstract, but it should be interpreted cautiously: it was derived from an exploratory secondary analysis, not from a pre-specified primary comparison, and the absence of a clear threshold elsewhere in the same analysis means the number is not a sharp cutoff. [E tier for definitive claims; exploratory signal only]

For other risk factors, the authors highlighted LDL cholesterol. They suggested that keeping LDL cholesterol below 80 mg/dL may be an important target for minimizing stroke risk. As with the glycemic findings, this is an observational estimate from a secondary analysis and does not establish a treatment threshold on its own. Blood pressure and HDL cholesterol were also analyzed as part of the same framework, and readers should consult the full paper for the detailed curves and confidence intervals.

Several limitations apply. The number of severe hypoglycemia events was very small, which is the reason the trial population was considered low-risk for this outcome, but it also limits how precisely any safety threshold can be estimated. The analysis is secondary to a trial, the population was Japanese adults, and the findings may not transfer directly to other ethnic groups, drug regimens, or healthcare settings. The study is also a single trial analysis, so it should be weighed alongside other randomized and observational evidence on glycemic targets.

What this means for you

Study details

Sources

1. Search for the glycated hemoglobin target minimizing mortality among people with type 2 diabetes with rare incidence of treatment-related severe hypoglycemia: Epidemiologic analysis of J-DOIT3 randomized controlled trial. *PLoS One*. PubMed. https://pubmed.ncbi.nlm.nih.gov/42912779/

2. ClinicalTrials.gov. Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases (J-DOIT3). NCT00300976. https://clinicaltrials.gov/study/NCT00300976

```